Norgine's Performance in 2017 and Priorities for 2018

AMSTERDAM, February 26, 2018 /PRNewswire/ --


- Continues long track record of growth. 2017 Net Sales were EUR345million, up 17
per cent 
- Receives European approval and launch PLENVU(R) 
- Strengthens its position with the acquisition of Merus Labs International Inc. for
C$342m 
- Norgine's products used by over 15 million patients  


Norgine continues to execute its Vision 2020:


- drive the performance of its products through its European and Australian
infrastructure
- accelerate its growth strategy


(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

PRODUCTS 

In house products: 


- MOVICOL(R) - despite generic competition our leading anti-constipation product
maintained its leading position with sales declining slightly to EUR157million (2016:
EUR159million)
- MOVIPREP(R) - our 2Litre bowel preparation for colonoscopy - achieved sales of
EUR57million, up 7% (2016: EUR53million)
- PLENVU(R) - received European approval and launched the first 1Litre bowel preparation
for colonoscopy


Key in-licensed products: 


- XIFAXAN(R)  - our hepatic encephalopatic treatment - saw sales of EUR51million, up
24% (2016: EUR41million)
- LYMPHOSEEK(R) - new radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in
adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of
the oral cavity - launched in Denmark, the Netherlands and the UK


Key acquired products: 


- Merus Labs International Inc. portfolio - acquired 12 established products
including SINTROM(R), EMSELEX(R), ELANTAN(R), ISOKET(R), DEPONIT(R), SALAGEN(R) and
ESTRADERM(R) which are sold across Europe and in other selected markets and VANCOCIN(R)
 which is sold in Canada. Contributed to EUR31million since acquisition on 17 July
2017


NORGINE  STRENGHTENS ITS POSTION AS THE 'GO TO' EU SPECIALIST PHARMA COMPANY PARTNER OF CHOICE  


- Merus Labs International Inc. This acquisition increased Norgine's scale and
profitability, helping to strengthen the business and attract new opportunities in the
future
- Apharm s.r.l. Norgine expanded its partnership with Apharm s.r.l by entering into an
exclusive distribution deal for ZIVEREL(R) PLUS, a line extension of ZIVEREL(R). This
deal expands on Norgine's existing collaboration with Apharm s.r.l. under which
Norgine is distributing ZIVEREL(R) in Europe, Australia and New Zealand


Peter Stein, CEO of Norgine: "2017 was a transformational year for Norgine. We successfully executed our strategy as the European Specialist Pharma Company to grow like for like sales of our existing products, gain approval of PLENVU(R) in Europe and acquire and integrate Merus Labs International Inc. Our strategy is working. We have a solid foundation for sustained growth in revenue and profitability. 2018 is a year of acceleration for Norgine. We will continue to focus on maximising the sales of our existing products while also pursuing new opportunities to bring transformative products to patients".

Video - https://youtu.be/g1LMgln1O2o

Listen to Peter Stein, CEO of Norgine discussing 2017 performance and 2018 objectives  

Media Contact: 

Isabelle Jouin, T: +44(0)1895-453643

Follow us @norgine 

View the full press release on http://www.norgine.com/media



Photo:
http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg




PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234